IL5 and eosinophilic granulomatosis with polyangiitis: Newly licensed treatments have already been integrated with the therapeutic armamentarium for adult AAV, such as avacopan (targeting the complement component C5a) [129], recommended as induction therapy in MPA/GPA, and mepolizumab (which reduces eosinophilic infiltration by blocking IL-5), recommended for induction and maintenance in EGPA [130].